Brief: U.S. FDA Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten)
01/06/2026 12:15
BRIEF-U.S. FDA Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) June 1 (Reuters) - Bristol-Myers Squibb Co BMY.N:
U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS FOR PRIORITY REVIEW BRISTOL MYERS SQUIBB’S SUPPLEMENTAL NEW DRUG APPLICATION FOR CAMZYOS (MAVACAMTEN) TO TREAT ADOLESCENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
BRISTOL-MYERS SQUIBB CO - FDA GRANTS PRIORITY REVIEW TO CAMZYOS WITH PDUFA DATE SEPT 30, 2026
Source text: ID:nBw9JqBnra
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC